The concomitant utilization of buprenorphine and CYP3A4 inducers can minimize the plasma focus of buprenorphine [see CLINICAL PHARMACOLOGY], most likely resulting in lessened efficacy or onset of a withdrawal syndrome in sufferers who have developed Actual physical dependence to buprenorphine.Along with its required effects, a medicine could cause